An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

REGN-COV2 Antibody Cocktail

Chemical Namecasirivimab and imdevimab
Dosage FormInjection (intravenous; 120 mg/mL casirivimab/120 mg/mL imdevimab)
Drug ClassMonoclonal antibodies
SystemRespiratory
CompanyRegeneron Pharmaceuticals
Approval Year2020

Indication

  • For the treatment of mild to moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progressing to severe COVID19 and/or hospitalization.
Last updated on 11/24/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
REGN-COV2 Antibody Cocktail (Casirivimab and imdevimab) Prescribing Information2020Regeneron Pharmaceuticals, Inc. Tarrytown, NY
Document TitleYearSource
A phase 3, randomized, double-blind, placebo-controlled study assessing the efficacy and safety of anti-spike SARS-CoV-2 monoclonal antibodies in preventing SARS-CoV-2 infection in household contacts of individuals infected with SARS-CoV-2.2020Regeneron Pharmaceuticals
A master protocol assessing the safety, tolerability, and efficacy of anti-spike (S) SARS-CoV-2 monoclonal antibodies for the treatment of ambulatory patients with COVID-19.2020Regeneron Pharmaceuticals